Antibody Contract Manufacturing Market Report 2026

Antibody Contract Manufacturing Market Overview

• Antibody Contract Manufacturing market size has reached to $16.79 billion in 2025 • Expected to grow to $34.72 billion in 2030 at a compound annual growth rate (CAGR) of 15.8% • Growth Driver: Surge In Clinical Trials Fuels The Antibody Contract Manufacturing Market Growth • Market Trend: Innovative Single-Use Technology Enhances Antibody-Drug Conjugate Manufacturing Efficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Antibody Contract Manufacturing Market?

Antibody contract manufacturing refers to outsourcing the production and manufacturing of antibodies to specialized contract manufacturing organizations (CMOs). These CMOs are equipped with the expertise, infrastructure, and resources necessary to manufacture antibodies on behalf of pharmaceutical and biotechnology companies. The main products of antibody contract manufacturing are monoclonal antibodies, polyclonal antibodies, and others. Monoclonal antibodies (mAbs) are antibodies that are designed to target a specific antigen, and antibody contract manufacturing plays a significant role in producing monoclonal antibodies at a large scale, ensuring consistent quality and quantity for therapeutic or diagnostic applications. They are developed from sources such as mammals and microbes at preclinical, clinical, and commercial scales of operation that are used by end users such as biopharmaceutical companies, research laboratories, and others.

What Is The Antibody Contract Manufacturing Market Growth Forecast?

The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $34.72 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to growing demand for commercial-scale antibody production, increasing investments in next-generation biologics, rising focus on cost-efficient manufacturing models, expansion of personalized medicine pipelines, increasing regulatory approvals for antibody therapies. Major trends in the forecast period include expansion of large-scale antibody manufacturing capacity, rising adoption of single-use bioprocessing systems, growing demand for bispecific antibodies and adcs, increased focus on flexible and scalable manufacturing models, enhanced emphasis on regulatory compliance and quality control.

What Is The Driver Of The Antibody Contract Manufacturing Market?

The rising number of clinical trials is expected to propel the growth of the antibody contract manufacturing market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The number of clinical trials involving antibody-based therapeutics or diagnostics expands, for high-quality antibodies, ensuring a timely and compliant supply for clinical trials. For instance, in May 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, in all 50 states of the United States and 221 countries, the number of registered clinical trials studies climbed from 399,499 in 2022 to 437,533 in 2023. Additionally, around 241,498 studies, or 53% of the total, were registered outside the United States, compared to 140,492 studies (31%) registered just in the United States. Therefore, the rising number of clinical trials is driving the growth of the antibody contract manufacturing industry.

Key Players In The Global Antibody Contract Manufacturing Market

Major companies operating in the antibody contract manufacturing market are Lonza Group AG, Catalent Inc, Samsung Biologics Co Ltd, Wuxi Biologics Cayman Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim BioXcellence, AGC Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie Inc, Charles River Laboratories International Inc, mAbxience, KBI Biopharma Inc, Abzena Ltd, Just‑Evotec Biologics, Northway Biotech, Cerbios‑Pharma, Scorpius BioManufacturing, Lotte Biologics, Rentschler Biopharma SE, Cytiva (Life Sciences CDMO), Xcellon Biologics, Celonic AG, Syngene International Ltd

Global Antibody Contract Manufacturing Market Trends and Insights

Major companies operating in the antibody contract manufacturing market are focusing on developing innovations, such as single-use technology that minimizes cross-contamination risks and reduces operational costs. Single-use technology (SUT) refers to disposable components and systems used in biopharmaceutical manufacturing processes. For instance, in September 2024, Merck & Co., a US-based pharmaceutical company, launched the Mobius ADC Reactor designed to enhance the manufacturing of antibody-drug conjugates. A new single-use reactor specifically designed for antibody drug conjugate manufacturing significantly enhances production efficiency by 70% compared to traditional stainless steel or glass methods. Its single-use design minimizes cross-contamination risks and operational costs, allowing for faster turnaround times. Additionally, advanced film technology improves bag strength and leak resistance, ensuring the integrity of highly potent active pharmaceutical ingredients. This innovation supports biopharmaceutical companies in producing critical therapies more safely and efficiently.

What Are Latest Mergers And Acquisitions In The Antibody Contract Manufacturing Market?

In September 2024, Agilent Technologies, a US-based provider of analytical and clinical laboratory technologies, instruments, software, services, and expertise, acquired BIOVECTRA for an undisclosed amount. With this acquisition, Agilent aims to enhance its contract development and manufacturing capabilities, expand its biologics and targeted therapeutics portfolio, and support advanced modalities including gene editing. BIOVECTRA is a Canada-based provider of contract development and manufacturing services (CDMO) specializing in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.

What Defines the Antibody Contract Manufacturing Market?

The antibody contract manufacturing market includes revenues earned by entities by providing services such as cell line development, process optimization, and the manufacturing of clinical trial materials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antibody Contract Manufacturing Market Report 2026?

The antibody contract manufacturing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antibody contract manufacturing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.